Patient Derived Xenograft (PDX) Models Market Demand Forecast and Leading Players Analysis Through 2030
The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.
What Is the Estimated Market Growth Potential of the Patient Derived Xenograft (PDX) Models Market by 2030?
The patient derived xenograft (pdx) models market size has grown rapidly in recent years. It will grow from $0.47 billion in 2025 to $0.54 billion in 2026 at a compound annual growth rate (CAGR) of 15.8%. The growth in the historic period can be attributed to limited predictive capability of traditional cell line models, increasing cancer research initiatives, reliance on animal models for drug testing, growing demand for translational oncology studies, expansion of academic and pharmaceutical research collaborations.
The patient derived xenograft (pdx) models market size is expected to see rapid growth in the next few years. It will grow to $0.92 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to rising adoption of pdx models for precision medicine, increasing investment in humanized mouse and rat models, growth of co-clinical trial programs, expansion of contract research services offering pdx solutions, increasing use of pdx models for immunotherapy and targeted therapy evaluation. Major trends in the forecast period include increasing adoption of pdx models for preclinical drug development, rising focus on personalized cancer research using pdx models, growing integration of digital platforms for tumor data management, increasing utilization of humanized and genetically modified models, rising expansion of co-clinical trials leveraging pdx models.
Claim your free report sample now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp
What Are the Leading Growth Factors in the Patient Derived Xenograft (PDX) Models Market?
The demand for personalized medicine is expected to propel the growth of the patient-derived xenograft (PDX) models market going forward. Personalized medicine involves tailoring medical treatment to each patient's specific characteristics, considering factors such as genetics, environment, and lifestyle. The demand for personalized medicine is increasing due to advancements in genomic research, which enable tailored treatments based on individual genetic profiles, leading to more effective and targeted healthcare outcomes. Patient-derived xenograft (PDX) models aid personalized medicine by allowing the testing of individual patient tumors to predict treatment responses and tailor therapies accordingly. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from six approvals in 2022. Therefore, the demand for personalized medicine drives the patient-derived xenograft (PDX) models market growth.
How Is the Patient Derived Xenograft (PDX) Models Market Arranged by Segment Classification?
The patient derived xenograft (pdx) models market covered in this report is segmented –
1) By Type: Mice Models, Rat Models
2) By Technique: Heterotopic Implantation, Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models, Lung Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Other Tumor Models
4) By Application: Preclinical Drug Development, Precision Medicine, Co-Clinical Trials, Basic Cancer Research
5) By End-User: Academic And Research Organizations, Contract Research Organizations, Pharmaceutical And Biotechnological Companies, Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice), Humanized Mice Models, Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models, Humanized Rat Models, Genetically Modified Rat Models
Which Trends Are Positively Affecting the Patient Derived Xenograft (PDX) Models Market Expansion?
Major companies operating in the patient-derived xenograft (PDX) models market are developing innovative models with in vivo bioluminescence imaging capabilities to enable real-time monitoring of tumor growth. In vivo bioluminescence imaging helps PDX models by enabling noninvasive real-time monitoring of tumor metastasis and treatment responses, enhancing the effectiveness of preclinical research in drug development. For instance, in March 2024, InVitro Research Solutions Private Limited, an India-based Contract Research Organization (CRO), launched an innovative orthotopic model of human glioblastoma in NSG-SGM3 mice by using patient-derived xenografts (PDX) and in vivo bioluminescence imaging. This model aims to enable personalized treatment of glioblastoma, the most common and aggressive type of brain cancer. These models are critical for understanding glioblastoma biology and evaluating new targeted therapies and immunotherapies to improve outcomes.
Who Are the Top Competitors in the Patient Derived Xenograft (PDX) Models Market?
Major companies operating in the patient derived xenograft (pdx) models market are WuXi AppTec Co Ltd, Charles River Laboratories International Inc, The Jackson Laboratory, Inotiv Inc, Taconic Biosciences Inc, Crown Bioscience Inc, Champions Oncology Inc, Certis Oncology Solutions Inc, EPO Experimental Pharmacology & Oncology Berlin‑Buch GmbH, InnoSer, Envigo, Oncodesign Services SA, Horizon Discovery Ltd, Pharmatest Services Ltd, Hera BioLabs, Xenopat, Noble Life Sciences, Medicilon, TheraIndx Life Sciences, Invivocue, InVitro Research Solutions Private Limited, NexusPharma, Mediford Corporation, GemPharmatech Co Ltd.
Get the full patient derived xenograft (pdx) models market report here:
https://www.thebusinessresearchcompany.com/report/patient-derived-xenograft-pdx-models-global-market-report
Which regions are expected to dominate the Patient Derived Xenograft (PDX) Models Market during the forecast period?
North America was the largest region in the patient derived xenograft (PDX) models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (pdx) models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment